Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein

Journal of Experimental Therapeutics and Oncology

Volumn 2, Issue 2, 2002, Pages 107-120

  Mayer, Lawrence D ^a,b   Lim, Kye Taek ^a   Hartley, Daria ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Chonnam National University   (South Korea)

Author keywords

Cancer; Chemotherapy; Multidrug resistance

Indexed keywords

ADENOSINE TRIPHOSPHATE; DOXORUBICIN; DRUG RESIDUE; GLYCOPROTEIN P; VERAPAMIL;

ANIMAL; ARTICLE; BIOAVAILABILITY; DOSE RESPONSE; DRUG RESISTANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEUKEMIA P 388; METABOLISM; MOUSE; MULTIDRUG RESISTANCE; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; ANIMAL CELL; CELL INTERACTION; CELL TRANSPORT; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG DESIGN; EMBRYO; EXPOSURE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADENOSINE TRIPHOSPHATE; ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESIDUES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; LEUKEMIA P388; MICE; P-GLYCOPROTEIN; PROTEIN BINDING; VERAPAMIL; ANIMAL; SUPPORT, NON-U.S. GOV'T;

EID: 0036009628     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1359-4117.2002.1009x.x     Document Type: Article

References (40)

1. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
2. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability
3. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
4. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers
5. Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns
6. Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors
7. Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of Adriamycin in resistant P388 mouse leukemia cells
8. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumor cells
9. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine
10. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro
11. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma
12. Cyclosporin A and its analogues as modifiers of Adriamycin and vincristine resistance in a multidrug-resistant human lung cancer cell line
13. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance
14. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
15. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma
16. Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients
17. A Phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory mycloma
18. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma
19. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil
20. Phase I and pharmacokinetic study of d-verapamil and doxorubicin
21. Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent d-verapamil
22. A Phase I study of paclitaxel with R-verapamil in metastatic breast cancer
23. A Phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin A in an attempt to reverse multidrug resistance
24. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin
25. Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer
26. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane-bound glycoprotein
27. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells
28. P-glycoprotein (Pgp) and drug resistance - Time for reappraisal?
29. 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines
30. 1-acid glycoprotein
31. Pharmacological characterization of multidrug-resistant MRP-transfected human tumor cells
32. Targeted delivery of a substrate for P-glycoprotein to renal cysts in vitro
33. The cationic lipid stearlyamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: Implications for drug delivery
34. Decreased potency of MDR modulators under serum conditions determined by a functional assay
35. The reversal of multidrug resistance in cancer
36. Clinical trials of agents that reverse multidrug resistance
37. Verapamil reversal of chloroquine resistance in the malarial parasite Plasmodium falciparum is specific for resistant parasites and independent of the weak base effect
38. Ultrastructure localization of daunorubicin in multidrug-resistant cultured cells with modulation of the multidrug transporter
39. Analysis of the interactions of SDZ PSC 833 ([3′-keto-Bmt1]-val2-cyclosporine), a multidrug resistance modulator, with P-glycoprotein
40. Extent and persistence of P-glycoprotein inhibition in multidrug resistance P388 cells after exposure to resistance-modifying agents